TheraRadar

Pharma Intelligence, Simplified

Landscape → Oncology

Neuroendocrine Tumors

403 clinical trials

206 active
/
403 total (since 2015)
64
Phase 1 Active
130 total
116
Phase 2 Active
221 total
45
Phase 3 Active
79 total
17
Phase 4 Active
38 total

Top Sponsors (Industry)

Sorted by active Active Done Failed
Vertex Pharmaceuticals Incorporated 3 1 0
Crinetics Pharmaceuticals Inc. 3 0 0
ITM Solucin GmbH 3 0 0
Quoin Pharmaceuticals 3 0 0
Jiangsu HengRui Medicine Co., Ltd. 3 0 0
Advanced Accelerator Applications 2 1 0
Shanghai Shengdi Pharmaceutical Co., Ltd 2 1 0
Merck 2 0 0
RayzeBio, Inc. 2 0 0
HTA Co., Ltd. 2 0 0
Novartis 1 3 0
Roche 1 1 1
Capricor Inc. 1 1 0
Camurus AB 1 1 0
Orano Med LLC 1 0 1
NCT05356195 ACTIVE NOT RECRUITING
Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT)
Vertex Pharmaceuticals Incorporated n=16
NCT03375320 ACTIVE NOT RECRUITING
Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
National Cancer Institute (NCI) n=298
NCT06943755 RECRUITING
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
Exelixis n=440
NCT07087054 RECRUITING
Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
Crinetics Pharmaceuticals Inc. n=141
NCT06760546 RECRUITING
A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)
Rhythm Pharmaceuticals, Inc. n=39
NCT04706910 RECRUITING
18F-DOPA II - PET Imaging Optimization
University of Alberta n=800
NCT07210723 RECRUITING
A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy
Kardigan, Inc. n=332
NCT07275814 RECRUITING
A Study of a Gadolinium-Based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Central Nervous System (CNS) Lesions
Shanghai Shengdi Pharmaceutical Co., Ltd n=250
NCT06784752 RECRUITING
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
Novartis Pharmaceuticals n=240
NCT05326087 NOT YET RECRUITING
Comparison of the Euploid Rate of Blastocyst Between PPOS and GnRH Antagonist Protocol in Women With PCOS Undergoing PGT-A
ShangHai Ji Ai Genetics & IVF Institute n=204
NCT03972488 ACTIVE NOT RECRUITING
Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET
Advanced Accelerator Applications n=226
NCT05477576 RECRUITING
Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
RayzeBio, Inc. n=288
NCT06065657 RECRUITING
Effect of Nutritional Ketosis on Alcohol Metabolism
University of Pennsylvania n=20
NCT05238519 ACTIVE NOT RECRUITING
Improved Diagnosis of Familial Hypercholesterolemia Across the Northland (ID-FH)
Essentia Health n=300
NCT07275723 RECRUITING
A Study of a Gadolinium-Based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Body Parts (Non-Central Nervous System) Lesions
Shanghai Shengdi Pharmaceutical Co., Ltd n=306
NCT07326540 NOT YET RECRUITING
Efficacy and Safety of BV100 Plus Low Dose Polymyxin B Versus Colistin Plus High-dose Ampicillin/Sulbactam in Patients With Hospital-acquired or Ventilator-associated Bacterial Pneumonia Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex
BioVersys SAS n=248
NCT06917690 RECRUITING
A Study to Learn About the Safety and Efficacy of the Drug Oleogel-S10 in Japanese Patients With Epidermolysis Bullosa
Chiesi Farmaceutici S.p.A. n=6
NCT05126758 ACTIVE NOT RECRUITING
A Study of Deramiocel (CAP-1002) in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy
Capricor Inc. n=106
NCT05918302 RECRUITING
Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.
Grupo Espanol de Tumores Neuroendocrinos n=120
NCT06672237 ACTIVE NOT RECRUITING
A Phase 3 Study of NTLA-2001 in ATTRv-PN
Intellia Therapeutics n=50
NCT05477563 RECRUITING
Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease
Vertex Pharmaceuticals Incorporated n=26
NCT05050942 ACTIVE NOT RECRUITING
A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET
Camurus AB n=332
NCT04208529 ENROLLING BY INVITATION
A Long-term Follow-up Study in Participants Who Received CTX001
Vertex Pharmaceuticals Incorporated n=160
NCT05521438 ACTIVE NOT RECRUITING
Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome
Quoin Pharmaceuticals n=30
NCT07185672 RECRUITING
PRRT Versus PRRT Plus Chemotherapy in GEP NET (PReCedeNT Trial)
Tata Memorial Hospital n=162
NCT05387603 RECRUITING
Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors.
Lund University Hospital n=300
NCT04919226 ACTIVE NOT RECRUITING
Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE
ITM Solucin GmbH n=259
NCT07165886 RECRUITING
Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. n=243
NCT05459844 ACTIVE NOT RECRUITING
A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs
Sinotau Pharmaceutical Group n=196
NCT06878664 RECRUITING
Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors
Grupo Espanol de Tumores Neuroendocrinos n=166
NCT07119242 ACTIVE NOT RECRUITING
Evaluate the Diagnostic Efficacy, Pharmacokinetics and Safety of 68Ga-DOTATATE Injection PET/CT in NETs
HTA Co., Ltd. n=95
NCT06953466 RECRUITING
Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome
Quoin Pharmaceuticals n=8
NCT04588311 RECRUITING
ErythroPOietin Alfa to Prevent Mortality and Reduce Severe Disability in Critically Ill TRAUMA Patients
Australian and New Zealand Intensive Care Research Centre n=2,500
NCT07057622 RECRUITING
A Phase III Clinical Study to Compare the Safety and Efficacy of 177Lu-DOTATATE Injection and Long-acting Oxytrexine in Adult Patients With NETs
HTA Co., Ltd. n=184
NCT06091748 RECRUITING
Gallium (68Ga) Edotreotide PET/CT for Imaging Patients With Gastrointestinal Pancreatic Neuroendocrine Tumors
Jiangsu HengRui Medicine Co., Ltd. n=66
NCT04042402 ACTIVE NOT RECRUITING
Long Term Extension Study in Patients With Primary Hyperoxaluria
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company n=75
NCT03049189 ACTIVE NOT RECRUITING
Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients
ITM Solucin GmbH n=309
NCT05789056 RECRUITING
Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndrome
Quoin Pharmaceuticals n=20
NCT06855095 RECRUITING
Absorbed Tumor Dose in Peptide Receptor Radionuclide Therapy with Long-acting Somatostatin Analogues - ATSA Trial
The Netherlands Cancer Institute n=39
NCT06850311 RECRUITING
Herbal Ointment in Treating Atopic Dermatitis Topically
En Chu Kong Hospital n=66
NCT05447208 RECRUITING
Effect of GH on the Blastocyst Euploid Rate in AMA Patients
ShangHai Ji Ai Genetics & IVF Institute n=400
NCT06678425 NOT YET RECRUITING
This Study is About the Efficacy of Repetitive Peripheral Magnetic Stimulation on the Treatment of Shoulder Subluxation in Subacute Stroke Patients.
Mahidol University n=20
NCT04847505 RECRUITING
68Ga-DOTA-TATE PET/CT Imaging in NETs
Centre de recherche du Centre hospitalier universitaire de Sherbrooke n=5,000
NCT05749289 RECRUITING
Application of Al18F-octreotide PET/CT in Neuroendocrine Tumor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences n=400
NCT05884255 RECRUITING
An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.
Jiangsu HengRui Medicine Co., Ltd. n=220
NCT05915728 COMPLETED
A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Any Known or Suspected Problems of the Body (Except Brain or Spinal Cord-related Problems)
Bayer n=404
NCT03655678 COMPLETED
A Safety and Efficacy Study Evaluating CTX001 in Participants With Transfusion-Dependent β-Thalassemia
Vertex Pharmaceuticals Incorporated n=59
NCT05856526 TERMINATED
A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Netherton Syndrome
Boehringer Ingelheim n=43
NCT05915702 COMPLETED
A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Known or Suspected Brain or Spinal Cord-related Problems
Bayer n=303
NCT05915026 COMPLETED
A Study to Learn How Gadoquatrane Moves Into, Through, and Out of the Body and How Safe it is in Children (From Birth to <18 Years), Who Will Undergo a Contrast Enhanced MRI (Quanti Pediatric)
Bayer n=93
NCT05425745 COMPLETED
Evaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifying Therapies.
NewAmsterdam Pharma n=354
NCT04414748 COMPLETED
Comparison of the Euploid Rate of Blastocyst Between PPOS and GnRH Antagonist Protocol in Patients Undergoing PGT-A
ShangHai Ji Ai Genetics & IVF Institute n=400
NCT02840149 COMPLETED
SUV on 68Ga-DOTATATE PET/CT and Ki-67 Index in Neuro-Endocrine Tumors
Jewish General Hospital n=45
NCT03479476 COMPLETED
A Trial of Metformin in Individuals With Fragile X Syndrome
University of California, Davis n=120
NCT03563053 TERMINATED
Extension Treatment Using EryDex System in Patients With AT Who Participated in the ATTeST-IEDAT-02-2015 Study
Quince Therapeutics S.p.A. n=104
NCT04852679 COMPLETED
Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs
Ipsen n=43
NCT06413082 COMPLETED
Pharmacogenetics of Torasemide and Spironolactone in Hypertension Treatment
Ospedale San Raffaele n=38
NCT02770807 COMPLETED
Intra-Erythrocyte Dexamethasone Sodium Phosphate in Ataxia Telangiectasia Patients
Quince Therapeutics S.p.A. n=176
NCT04200352 TERMINATED
A Study to Test if TEV-50717 is Safe and Effective in Relieving Abnormal Involuntary Movements in Cerebral Palsy
Teva Branded Pharmaceutical Products R&D, Inc. n=44
NCT03179631 COMPLETED
Long-Term Outcomes of Ataluren in Duchenne Muscular Dystrophy
PTC Therapeutics n=360
NCT03813238 COMPLETED
A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents
Teva Branded Pharmaceutical Products R&D, Inc. n=63
NCT04760314 COMPLETED
A Study of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroids in Japanese Participants With Moderate-to-Severe Atopic Dermatitis
Eli Lilly and Company n=286
NCT03136328 COMPLETED
Diagnosis and Staging of Neuroendocrine Tumors (NETs) Utilizing 68Ga-DOTATOC PET/CT Scan
Montefiore Medical Center n=11
NCT02589821 COMPLETED
Phase III Study of Surufatinib in Treating Advanced Pancreatic Neuroendocrine Tumors
Hutchison Medipharma Limited n=195
NCT02588170 COMPLETED
Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors
Hutchison Medipharma Limited n=219
NCT03894046 COMPLETED
Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex
Entasis Therapeutics n=207
NCT03673943 COMPLETED
Imaging of Patients With Known or Suspected Somatostatin Receptor Positive Neuroendocrine Tumors Using Cu64-DOTATATE
Radiomedix, Inc. n=63
NCT03590119 COMPLETED
Intra-arterial Lutetium-177-dotatate for Treatment of Patients With Neuro-endocrine Tumor Liver Metastases
Marnix Lam n=26
NCT02608203 COMPLETED
[68 Ga]-DOTANOC PET/CT in GEP-NETs
Assistance Publique Hopitaux De Marseille n=18
NCT02683941 TERMINATED
Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumours
Ipsen n=77
NCT04552847 COMPLETED
Al18F-NOTA-octreotide PET Imaging in Neuroendocrine Tumors
Universitaire Ziekenhuizen KU Leuven n=85
NCT03042416 COMPLETED
18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety
University of Alberta n=400
NCT03627767 COMPLETED
Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring Subjects
Pfizer n=1,235
NCT04877067 COMPLETED
Therapy of Toxic Optic Neuropathy Via Combination of Stem Cells With Electromagnetic Stimulation
Ankara Universitesi Teknokent n=18
NCT03720470 COMPLETED
Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy
Pfizer n=838
NCT03054428 COMPLETED
Efficacy and Safety of Dupilumab in Participants ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis
Regeneron Pharmaceuticals n=251
NCT02465112 TERMINATED
Metabolic Radiotherapy After Complete Resection of Liver Metastases in Patient With Digestive Neuroendocrine Tumor
GERCOR - Multidisciplinary Oncology Cooperative Group n=4
NCT02806141 TERMINATED
Aerosolized Plus Intravenous vs. Intravenous Colistin for VAP Due to Pandrugs-resistant A. Baumannii in Neonates
Hat Yai Medical Education Center n=204
NCT02084628 TERMINATED
Magnetic Resonance Imaging of the Liver in Children 0-2 Months of Age With an Intravenous Injection of Eovist/Primovist Which is a Contrast Agent
Bayer n=1

Data: ClinicalTrials.gov